selegiline / Generic mfg. - LARVOL DELTA

Selegiline Improved Oxidative and Inflammatory Stress Factors in Gentamicin-Induced Nephrotoxicity in Human Renal Tubular Epithelial Cells. (PubMed, Int J Prev Med) - "This research showed that selegiline increases cell viability, total antioxidant capacity, and interleukin 10 as well as decreases the amount of reactive oxygen species, malondialdehyde, and interleukin 6 against the effects of gentamicin-induced nephrotoxicity. These findings show that selegiline can have protective effects on kidney damage caused by gentamicin and by reducing oxidative stress and inflammation, it can be proposed as a promising treatment option to reduce the side effects of gentamicin."

Journal • Inflammation • IL10 • IL6

Catecholaminergic storm and extreme blood pressure lability induced by combined levodopa/benserazide, selegiline, and piribedil in Parkinson's disease: a case report. (PubMed, Neurol Sci) - "This case demonstrated that combined dopaminergic therapy could induce catecholamine storm via synergistic effects, leading to life-threatening fluctuations in BP. Timely identification and adjustment of treatment regimens could effectively reverse cardiovascular risk. However, it was crucial to carefully consider the balance between the progression of motor symptoms and changes in medication treatment."

Journal • Cardiovascular • CNS Disorders • Fatigue • Movement Disorders • Parkinson's Disease

Determination of R/S-enantiomers of methamphetamine and amphetamine in human hair with chiral stationary phase LC-MS/MS. (PubMed, Bioanalysis) - "As the synthetic abused drug with high addictive potential, methamphetamine (METH) and its major metabolite amphetamine (AMP) are chiral compounds. Conversely, only the R-enantiomer was detected in the hair of a selegiline user. This research enables precise enantiomer differentiation, offering critical insights into drug metabolism and forensic discrimination between illicit METH abuse and legitimate selegiline treatment."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Effect of antidepressants on motor and functional recovery in stroke: a systematic review and meta-analysis. (PubMed, BMC Neurol) - "Certain antidepressants may enhance motor performance and independence in performing activities of daily living during post-stroke recovery among elderly patients. Fluoxetine was the most common antidepressant described in the literature with significant improvement in motor (FMMS) functional (BI) scales. However, substantial heterogeneity and potential study biases warrant cautious interpretation. Rigorous, large-scale RCTs are necessary to verify these findings and establish long-term safety profiles. They will also help define the optimal therapeutic strategies before routine clinical use is considered."

Journal • Retrospective data • Cardiovascular

Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus. (PubMed, Mol Divers) - "The drug-hub gene interaction network showed that Clenbuterol, Diethylstilbestrol, Selegiline and Isoflurophate predicted therapeutic drugs for the T1DM. Molecular docking and molecular dynamics simulation study revealed that CMNPD5805 and CMNPD30286 as potential inhibitors of FN1 (pdb id: 3M7P) a key biomarker in pathogenesis of T1DM. These findings promote the understanding of the molecular mechanism and clinically related molecular targets for T1DM."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • ADRB2 • BCL6 • CD74 • NOTCH1

Effects of MAO-B Inhibitors on Cognition in Patients with Parkinson’s Disease: A Systematic Network Meta-Analysis. (PubMed, Mov Disord Clin Pract) - "Rasagiline may provide global cognitive benefits in PD, but MAO-B inhibitors, including rasagiline, generally did not demonstrate significant effects on individual cognitive domains. These findings suggest limited cognitive impacts of MAO-B inhibitors beyond managing the motor symptoms. Further large-scale, long-term studies using domain-specific cognitive assessments are warranted to clarify their roles in cognitive performance in patients with PD."

Journal • Retrospective data • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease

Evaluation of Pyrrole Heterocyclic Derivatives as Selective MAO-B Inhibitors and Neuroprotectors. (PubMed, Molecules) - "Novel pyrrole-based derivatives were synthesized in high purity and yields (52-89%), with 17i and 17j displaying selective MAO-B inhibition (50-60%), comparable to Selegiline, and negligible MAO-A activity...Metabolic predictions suggest ester hydrolysis at the pyrrole ring as the main biotransformation pathway. Overall, 17i and 17j are promising lead compounds for developing therapeutics targeting oxidative stress-related neurodegenerative diseases, such as Parkinson's and Alzheimer's, supporting further in vivo studies."

Journal • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease

A PRELIMINARY REPORT ON ACCESSIBILITY, AFFORDABILITY, AND AVAILABILITY OF MEDICINES FOR PARKINSON (ADPD 2026) - "The most available medicines were for autonomic symptoms such as omeprazole (98.28%), sildenafil (89.7%), bisacodyl (84.5%), tadalafil (60.3%), and for psychiatric symptoms such as haloperidol (50%) and fluoxetine (48.3%). Among dopaminergic medicines, carbidopa/levodopa was always available in 19% of pharmacies, dopamine agonists in 13.8% (bromocriptine), 6.9% (cabergoline), and 1.7% (ropinirole), and monoamine oxidase B inhibitors in 1.72%...Affordable medicines were those always available in the reference public hospital pharmacy, such as the antipsychotics haloperidol and risperidone, the anticholinergic trihexyphenidyl, and the antidepressant fluoxetine... Similar to other low-income countries, there is poor access to PD medicines in Malawi`s pharmacies due to regulatory, supply chain, and financial barriers."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

EFFICACY OF MAO-B AND COMT INHIBITORS ON QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE: A BAYESIAN NETWORK META-ANALYSIS (ADPD 2026) - "Randomized controlled trials evaluating QoL using PDQ-39 or PDQ8 in patients treated with MAO-B inhibitors (rasagiline, selegiline, safinamide) or COMT inhibitors (entacapone, opicapone, tolcapone) were included. This network meta-analysis provides evidence that MAO-B inhibitors, particularly rasagiline and safinamide, may offer broader QoL benefits in patients with PD, especially in NMS such as emotional well-being. These findings support a more symptom-oriented and individualized treatment approach should be provided to patients with PD. Further well-designed head-to-head studies using standardized QoL measures and extended follow-up are needed to confirm these findings and guide clinical practice."

HEOR • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

EFFECTS OF MAO-B AND COMT INHIBITORS ON SLEEP DISTURBANCES IN PARKINSON'S DISEASE: A NETWORK META-ANALYSIS (ADPD 2026) - "Inclusion criteria involved (1) patients with PD, (2) intervention/comparator consisting of MAO-B inhibitors (safinamide, rasagiline, or selegiline) and COMT inhibitors (opicapone, entacapone, or tolcapone), and (3) outcomes of improvement in parameters for subjective and objective sleep in randomized controlled trials and cohort studies. Evidence has shown that safinamide is effective in improving objective sleep parameters in patients with PD. However, given the paucity of evidence and controlled, long-term studies, the effects of MAO-B and COMT inhibitors on sleep disturbances remain unclear. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on sleep profiles."

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

COMPARATIVE COGNITIVE EFFECTS OF MAO-B INHIBITORS IN PARKINSON'S DISEASE (ADPD 2026) - "We aimed to compare the effects of selegiline, rasagiline, and safinamide on global cognitive function and specific cognitive domains in patients with PD. Among MAO-B inhibitors, only rasagiline was associated with enhanced overall cognitive performance in PD, but domain-specific improvements were largely absent. These findings indicate that cognitive benefits beyond motor symptom control remain limited, and highlight the need for future long-term studies with domain-focused assessments to delineate therapeutic roles for MAO-B inhibitors in cognitive outcomes for PD patients."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Beyond Dysphagia in Parkinson's Disease: 3D Printing of Orally Disintegrating Tablets (ODTs) for Optimized Treatment. (PubMed, Pharmaceuticals (Basel)) - "Research indicates that selegiline ODT achieves a faster time to peak and higher relative bioavailability via partial buccal absorption, whereas carbidopa/levodopa ODTs are bioequivalent to immediate release tablets (with similar AUC/Cmax and approximately 1 h Tmax) without consistent motor advantages but with higher patient acceptability. Feasibility studies underscore stability considerations such as carbidopa, throughput and regulatory requirements (QbD/GMP), and bioequivalence information. We outline priorities to integrate 3D printed ODTs into PD care, aligning formulation, pharmacokinetics, and human factors to improve adherence and clinical outcomes."

Journal • Review • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease

MAO-B inhibition by selegiline blunts cardiac functions improved by high-fat diet: Role of inflammation, apoptosis, and calcium-handling. (PubMed, Curr Res Pharmacol Drug Discov) - "HFD induced proapoptotic processes, which were restored by selegiline. In conclusion, moderate obesity improves cardiac function through Ca2+ homeostasis and inflammatory processes and MAO-B inhibition reverses these effects."

Journal • Cardiovascular • Genetic Disorders • Inflammation • Obesity • Oncology • TNFA

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. (PubMed, Pharmaceuticals (Basel)) - " Findings suggest that bromocriptine, amantadine, and selegiline may represent effective dopaminergic antidepressants, particularly for treatment-resistant or atypical depression. Further large-scale, methodologically rigorous studies are needed to confirm their clinical utility."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

L-dopa induced iron accumulation in the ventral midbrain: the roles of sex and iron repletion (Neuroscience 2025) - "Vehicle (0.1% ascorbic acid), carbidopa+L-DOPA (5/20 mg/kg), or selegiline (0.3mg/kg) was administered via subcutaneous injection in all groups. These findings suggest that L-DOPA administration under iron-depleted-repleted conditions disrupts iron homeostasis by promoting iron uptake and reducing iron storage capacity, particularly in males. This sex-specific vulnerability to iron accumulation highlights the need for personalized PD therapies that consider both iron status and biological sex."

CNS Disorders • Movement Disorders • Parkinson's Disease • GFAP • TFRC

Current practices for diagnosis and management of Canine Cognitive Dysfunction Syndrome in the United States. (PubMed, Front Vet Sci) - "When managing their CCDS patients, pharmaceuticals are most often recommended, specifically selegiline...Results from this survey underscore there are still significant gaps in knowledge as to best practices for the diagnosis and management of CCDS. Clear CCDS diagnostic and management guidelines are needed to support veterinarians and address the therapeutic needs of patients."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Phenolic Derivatives of Astragalus aitosensis with Selective MAO-B Inhibition and Mitochondrial Protection. (PubMed, Molecules) - "Five of the phytochemicals-maackiain, cajanin, onogenin, afrormosin, and sayanedine-exhibited selective inhibition of human monoamine oxidase-B (MAO-B), with maackiain reducing activity by 45%, nearing the effect of selegiline...Structure-activity relationship (SAR) analysis highlighted the role of specific substituents and fused-ring systems in MAO-B inhibition. This study expands our knowledge of the phytochemical diversity of A. aitosensis and supports the therapeutic relevance of its phenolic compounds in neurodegenerative disorders such as Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Effectiveness of Medical Treatment on Survivability in Canine Cushing's Syndrome: A Systematic Review and Meta-Analysis. (PubMed, Animals (Basel)) - "Several pharmacological agents are available: trilostane, mitotane, ketoconazole, cabergoline, selegiline, and aminoglutethimide, but their comparative effects on survival remain unclear. In contrast, pooled survival rates at fixed intervals favored trilostane, with an 11% higher survival at 36 months (p = 0.005) and no heterogeneity observed (I2 = 0%). These findings suggest trilostane may offer long-term survival benefits over mitotane."

Journal • Retrospective data • Cushing’s Disease • Endocrine Disorders

Role of 5-Hydroxydecanoate in the Neuroprotective Activity of Diosmetin Against Rotenone-Induced Dopaminergic Toxicity in Rats. (PubMed, Protein Pept Lett) - "Diosmetin exhibits potent antioxidant and neuroprotective properties against rotenone-induced PD-like pathology. The combination of diosmetin and 5-HD offers a synergistic therapeutic potential, suggesting a promising approach for managing oxidative stress and mitochondrial dysfunction in PD."

Journal • Preclinical • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Selective detection of Selegiline in Parkinson's patient urine via CuAAC-mediated fluorescence quenching of Azide-modified carbon dots. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "The method shows high selectivity against interferents and achieves excellent percentage recovery values reaching (96.0-97.0 %) when applied to urine samples. Most importantly, the method was successfully applied to urine samples from Parkinsonism patients, providing a non-invasive route for selegiline determination that offers significant advantages over traditional invasive sampling methods."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson's Disease (MDS Congress 2025) - "Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment stability and demographic influences. No single add-on therapy demonstrated superior stability, highlighting comparable efficacy across options. Sex significantly influenced therapy adjustments, with females requiring more frequent modifications. These findings underscore the importance of personalized treatment strategies in fluctuating PD management."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson's Disease (MDS Congress 2025) - " Among 44 sporadic PD cases, 21 received MAOBIs (selegiline: 13, rasagiline: 8), 18 received levodopa, and 5 received dopamine agonists. Patients with less orthostatic hypotension and preserved postganglionic cardiac sympathetic function were more likely to benefit from MAOBIs. Their MAO-A inhibitory effect may suppress norepinephrine metabolism, enhancing motor function via dopamine activation. Therefore, PD patients with mild orthostatic hypotension and mild MIBG myocardial scintigraphy abnormalities, where endogenous norepinephrine is retained, may experience greater motor symptom improvement with MAOBIs."

CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion (MDS Congress 2025) - "Antiparkinsonian medications, L-DOPA, and a monoamine oxidase-B (MAO-B) inhibitor, selegiline are commonly used to treat PD... These findings suggest that L-DOPA administration under ID-IR conditions disrupts iron homeostasis by promoting iron uptake and reducing iron storage capacity, particularly in males. This sex-specific vulnerability to iron accumulation highlights the need for personalized PD therapies that consider both iron status and biological sex."

CNS Disorders • Movement Disorders • Parkinson's Disease • GFAP • TFRC

A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson's disease (DATSZ-PD study) (MDS Congress 2025) - "Selegiline or zonisamide have been suggested to have neuroprotective effects on dopamine neurons in patients with early PD. Motor function also tended to be preserved in both +SL and +ZN groups compared to LD alone group. Regarding QOL, mobility tended to be maintained in +SL group, and communication tended to be maintained in +SL and +ZN groups."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Monoamine oxidases are mediators of oxidative stress in human varicose Veins: interactions with obesity, inflammation, and angiotensin II. (PubMed, Mol Cell Biochem) - "Furthermore, the effect of selective MAO inhibition (clorgyline 10 μM for MAO-A, selegiline 10 μM for MAO-B) was tested ex vivo both at baseline and following acute stimulation with Ang II (100 nM)...In conclusion, MAO isoforms, in particular MAO-A, are upregulated in the human varicose veins and can be further induced by Ang II, especially in the setting of obesity associated with low-grade inflammation. MAO contributed to the local oxidative stress, which was significantly reduced by its pharmacological inhibition with MAO-A and B inhibitors, thus pointing to MAO as a potential therapeutic target in patients with CVD."

Journal • Genetic Disorders • Inflammation • Obesity • Varicose Veins • CRP